Irene C Kazhdan

US Patent:

20080108582, May 8, 2008

Filed:

Oct 27, 2004

Appl. No.:

10/578445

Inventors:

Irene Kazhdan - San Antonio TX, US

International Classification:

A61K 31/7088
C07H 21/00
C12N 15/63
A61P 35/00
C12N 15/64

US Classification:

514 44, 536 231, 4353201

Abstract:

The present invention provides a nucleic acid comprising a) a nucleotide sequence encoding one or more pro-apoptotic proteins, and b) a nucleotide sequence encoding one or more tumor-specific and/or tissue-specific promoters. Also provided is a method of treating cancer, comprising administering the compositions of this invention to a subject.

US Patent:

20090163431, Jun 25, 2009

Filed:

Feb 14, 2008

Appl. No.:

12/031139

Inventors:

Irene Kazhdan - San Antonio TX, US
Zhiqiang Han - Fenton MO, US
Zheng Jim Wang - San Antonio TX, US
Ting-Tung Chang - San Antonio TX, US
Robert A. Marciniak - San Antonio TX, US

Assignee:

Ontherex LLC - San Antonio TX

International Classification:

A61K 31/7088
C12N 5/06
C12N 15/00

US Classification:

514 44, 435375, 4353201

Abstract:

Methods and compositions for inhibiting PDX-1 are provided according to the present invention. An anti-PDX-1 agent included in inventive methods and compositions includes an antibody, an aptamer, an antisense oligonucleotide, a ribozyme and/or an inhibitory compound. Methods of inhibiting PDX-1 expression in a tumor cell are provided by the present invention which include contacting a tumor cell with an effective amount of an anti-PDX- agent highly or completely complementary to a specified region of an RNA molecule encoding PDX-1. Such an agent specifically hybridizes with the RNA molecule encoding PDX-1 and inhibits the expression of a PDX-1 gene in the tumor cell. Compositions including anti-PDX-1 siRNA and/or shRNA are described. Recombinant expression constructs encoding anti-PDX-1 siRNA or shRNA according to the present invention are described.

US Patent:

20070128116, Jun 7, 2007

Filed:

Jul 27, 2006

Appl. No.:

11/460500

Inventors:

Zheng Wang - San Antonio TX, US
Irene Kazhdan - San Antonio TX, US
Jian Gao - Helotes TX, US
Zhiqiang Han - San Antonio MO, US
Robert Marciniak - San Antonio TX, US

International Classification:

A61K 49/00
A61K 48/00
A61K 31/409
A61K 31/555

US Classification:

424009600, 514044000, 424009610, 514185000, 514410000

Abstract:

In the broadest sense an inventive conjugate includes a macrocyclic scaffold moiety incorporating at least one nitrogen atom. Through linkages to the ring, nitrogen atoms are bonded to at least one therapeutic species, or one cellular trafficking species, and preferably two or more types of trafficking species. The linkages between ring nitrogen atoms and agents are formed through N—C, N—S, N—O or N—N bonds. It is appreciated that more than one agent or agent species are coupled to a ring nitrogen atom through the inclusion of a branched carbon atom or secondary amine nitrogen within the intermediate between the agent and ring nitrogen atom. A disulfide bond intermediate between an agent and a linkage to the ring nitrogen is preferred in instances where intracellular release of the agent or trafficking species is desired. An optional metal ion is coordinated by the scaffolding moiety.